Health ProductsAdvisory

Archived –  Health Canada warns Canadians that certain lots of a sedative (Novo-Lorazem) may contain pills of a different drug

· Published by Health Canada · Official notice

Details

Alert type: Advisory
Category: Drugs
Issue: Product Safety, Important Safety Information
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Images

Details

Health Canada is advising consumers taking the sedative Novo-Lorazem to check their bottles for pills of a different shape and size, after a report alerted Health Canada to the presence of Novo-Glyburide (an oral hypoglycemic) pills in certain Novo-Lorazem bottles.

Novo-Glyburide is generally prescribed to diabetics to lower blood sugar. The use of this drug by non-diabetics or by diabetics already taking other medications used to lower blood sugar, might severely lower blood sugar, which in rare cases could result in coma and/or death.

Novo-Lorazem (0.5 mg) is a generic prescription sedative, manufactured by NovoPharm Limited and distributed throughout Canada. It is often prescribed for insomnia and for the treatment of symptoms associated with chemotherapy. The Drug Identification Number (DIN) for the product is 00711101, and the lot numbers affected are: 132932A and 132932B. The expiry date for these lots is October 2005.

There are significant differences in shape and marking between Novo-Lorazem and Novo-Glyburide pills. The primary difference is the shape and size of the tablets. Novo-Lorazem 0.5 mg tablets are white, round, flat-face tablets with "N" engraved on one side, and "0.5" engraved on the other. Novo-Glyburide tablets are white, capsule-shaped tablets with "N/N" engraved on one side and "5" engraved on the other. Novo-Glyburide tablets are also twice the size of Novo-Lorazem tablets. Below is a photograph of both Novo-Lorazem and Novo-Glyburide to help consumers distinguish between the two drugs.

Tablets of Lorazem and Glyburide

Consumers taking Novo-Lorazem are advised to check their bottles for capsule-shaped tablets with "N/N" engraved on one side. Tablets found to meet this description should not be consumed and the bottle should be returned to the pharmacy. Patients who suspect they may have consumed these tablets should contact their physician.

The affected lots are being recalled by the manufacturer, Novopharm Limited. The company is also working with Health Canada to identify and address the cause of the problem. Health Canada was first informed of the incident by the manufacturer following complaints received from a hospital and a pharmacy. In both those cases, the pharmacist noted the differently-shaped pills and they were not dispensed.

Health Canada is currently investigating whether there have been any adverse events reported in association with this incident. However, as of this time, no other complaints have been received by Health Canada. Health Canada continues to oversee the effectiveness of the recall.
 

Media enquiries

Margot Geduld
Health Canada
613-957-2983

Public enquiries

613-957-2991
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime